A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NA · SEQUENTIAL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 15
- Population
- ALL · 18 Years
- Duration
- 2025-05-19 to 2029-05-19
- Intervention
- Oral disulfiram
- Comparator
- Not reported
- Outcomes measured
- mean change in Best Corrected Visual Acuity (BCVA) score assessed by ETDRS — baseline to day 180; mean change in total contrast sensitivity score using Pelli-Robson charts — baseline to day 180; mean change in light-adapted microperimetry sensitivity assessed using standard MAIA microperimetry equipment — baselin…; mean change in outer retinal thickness assessed using Spectral Domain Optical Coherence Tomography (SD-OCT) — baseline…; mean change in fundus autofluorescence (FAF) — baseline to day 180; number of participants with retinal anatomy changes assessed using fundus photos — baseline to day 180; mean change in visual field perimetry using full-field stimulus test — baseline to day 180; mean change in isopter constriction using Goldmann visual field — baseline to day 180; mean change in size of scotomas using Goldmann visual field — baseline to day 180; mean change in cone and rod latency assessed using Full field electroretinogram (ffERG) — baseline to day 180; mean change in cone and rod amplitude assessed using Full field electroretinogram (ffERG) — baseline to day 180; mean change in cone and rod latency assessed using multifocal electroretinogram (mfERG) — baseline to day 180; mean change in cone and rod amplitude assessed using multifocal electroretinogram (mfERG) — baseline to day 180; mean change in National Eye Institute-Visual Functioning Questionnaire 25 composite score. — baseline to day 180
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.